Mink Therapeutics Inc (INKT) - News Archive

: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative allogeneic invariant natural killer T (allo-iNKT) cell therapies, showcased promising clinical data on its lead candidate, agen...

In a significant advancement in cancer treatment, MiNK Therapeutics, Inc. (NASDAQ: INKT), a pioneering clinical-stage biopharmaceutical company, showcased its innovative approach to tackling advanced gastroesophageal ca...

MiNK Therapeutics Presents Promising Clinical Activity of AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Gastric Cancer PatientsNew York, May 22, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a lead...

MiNK Therapeutics Secures $5.8 Million in Private Placement and Adds Board Observer for Accelerated Clinical Trials of MiNK-215NEW YORK, May 13, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a trailblazing clinical-sta...

MiNK Therapeutics Announces promising preclinical activity of MiNK-215 against colorectal cancer liver metastases at AACRNew York, April 08, 2024 - MiNK Therapeutics, a clinical-stage biopharmaceutical company, revealed...

MiNK Therapeutics, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer. Led by Dr. Yelena Janjigia...

Severe acute respiratory distress syndrome (ARDS) is a life-threatening condition that presents various challenges for medical professionals. The development of effective therapies targeted towards improving survival ra...

:This article discusses the groundbreaking findings of a case report published in Oncogene by MiNK Therapeutics, Inc. The study highlights the potential of MiNK s allogeneic, off-the-shelf, invariant natural killer T (i...

Biotechnology company ImmunoScape and clinical-stage biopharmaceutical firm MiNK Therapeutics, Inc. (Nasdaq: INKT) have made a groundbreaking announcement; Both entities have teamed up to expedite the discovery and deve...